VNRX Relative Valuation
VNRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, VNRX is overvalued; if below, it's undervalued.
Historical Valuation
VolitionRX Ltd (VNRX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.32. The fair price of VolitionRX Ltd (VNRX) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：0.28
Fair
-1.86
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
VolitionRX Ltd. (VNRX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -2.09. The thresholds are as follows: Strongly Undervalued below -7.39, Undervalued between -7.39 and -4.74, Fairly Valued between 0.56 and -4.74, Overvalued between 0.56 and 3.21, and Strongly Overvalued above 3.21. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-2.19
EV/EBIT
VolitionRX Ltd. (VNRX) has a current EV/EBIT of -2.19. The 5-year average EV/EBIT is -3.79. The thresholds are as follows: Strongly Undervalued below -7.39, Undervalued between -7.39 and -5.59, Fairly Valued between -2.00 and -5.59, Overvalued between -2.00 and -0.20, and Strongly Overvalued above -0.20. The current Forward EV/EBIT of -2.19 falls within the Historic Trend Line -Fairly Valued range.
9.21
PS
VolitionRX Ltd. (VNRX) has a current PS of 9.21. The 5-year average PS is 170.66. The thresholds are as follows: Strongly Undervalued below -744.23, Undervalued between -744.23 and -286.78, Fairly Valued between 628.11 and -286.78, Overvalued between 628.11 and 1085.55, and Strongly Overvalued above 1085.55. The current Forward PS of 9.21 falls within the Historic Trend Line -Fairly Valued range.
-2.69
P/OCF
VolitionRX Ltd. (VNRX) has a current P/OCF of -2.69. The 5-year average P/OCF is -5.27. The thresholds are as follows: Strongly Undervalued below -9.98, Undervalued between -9.98 and -7.63, Fairly Valued between -2.92 and -7.63, Overvalued between -2.92 and -0.56, and Strongly Overvalued above -0.56. The current Forward P/OCF of -2.69 falls within the Overvalued range.
-2.65
P/FCF
VolitionRX Ltd. (VNRX) has a current P/FCF of -2.65. The 5-year average P/FCF is -4.58. The thresholds are as follows: Strongly Undervalued below -8.19, Undervalued between -8.19 and -6.39, Fairly Valued between -2.77 and -6.39, Overvalued between -2.77 and -0.96, and Strongly Overvalued above -0.96. The current Forward P/FCF of -2.65 falls within the Overvalued range.
VolitionRX Ltd (VNRX) has a current Price-to-Book (P/B) ratio of -0.90. Compared to its 3-year average P/B ratio of -9.83 , the current P/B ratio is approximately -90.84% higher. Relative to its 5-year average P/B ratio of -0.69, the current P/B ratio is about 30.17% higher. VolitionRX Ltd (VNRX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -31.50%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -23.47% , the current FCF yield is about -100.00% lower.
-0.99
P/B
Median3y
-9.83
Median5y
-0.69
-56.62
FCF Yield
Median3y
-31.50
Median5y
-23.47
Competitors Valuation Multiple
The average P/S ratio for VNRX's competitors is 0.00, providing a benchmark for relative valuation. VolitionRX Ltd Corp (VNRX) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 32.19%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of VNRX decreased by 48.10% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 474.52K to 627.28K.
The secondary factor is the Margin Expansion, contributed -30.27%to the performance.
Overall, the performance of VNRX in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is VolitionRX Ltd (VNRX) currently overvalued or undervalued?
What is VolitionRX Ltd (VNRX) fair value?
How does VNRX's valuation metrics compare to the industry average?
What is the current P/B ratio for VolitionRX Ltd (VNRX) as of Dec 05 2025?
What is the current FCF Yield for VolitionRX Ltd (VNRX) as of Dec 05 2025?
What is the current Forward P/E ratio for VolitionRX Ltd (VNRX) as of Dec 05 2025?